TY - JOUR
T1 - Olaparib in Patients with Pancreatic Cancer with BRCA1 / 2 Mutations
T2 - Results from the Targeted Agent and Profiling Utilization Registry Study
AU - Ahn, Eugene R.
AU - Rothe, Michael
AU - Mangat, Pam K.
AU - Garrett-Mayer, Elizabeth
AU - Calfa, Carmen J.
AU - Alva, Ajjai S.
AU - Suhag, Vijay
AU - Alese, Olatunji B.
AU - Dotan, Efrat
AU - Hamid, Omid
AU - Yang, Eddy S.
AU - Marr, Alissa S.
AU - Palmer, Martin C.
AU - Thompson, Forrest L.
AU - Yost, Kathleen J.
AU - Gregory, Abigail
AU - Grantham, Gina N.
AU - Hinshaw, Dominique C.
AU - Halabi, Susan
AU - Schilsky, Richard L.
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2024
Y1 - 2024
N2 - PURPOSETargeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with advanced pancreatic cancer with BRCA1/2 mutations treated with olaparib are reported. METHODSEligible patients had advanced pancreatic cancer, measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options available. Genomic testing was performed in Clinical Laboratory Improvement Amendments-certified, College of American Pathologists-accredited site selected laboratories. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease of at least 16 weeks duration (SD16+) according to RECIST v1.1. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of stable disease, and safety.RESULTSThirty patients with BRCA1/2 mutations were enrolled from November 2016 to August 2019. The median number of reported previous therapies was 3 (range, 1-10). Two patients were not evaluable and excluded from efficacy analyses. Two patients with complete response, three with partial response and three with SD16+, were observed for DC and OR rates of 31% (90% CI, 18 to 40; P =.04) and 18% (95% CI, 6 to 37), respectively. The median PFS was 8 (95% CI, 8 to 15) weeks, and the median OS was 38 (95% CI, 21 to 65) weeks. Three patients had at least one drug-related grade 3 adverse event or serious adverse event of anemia, fever, or oral mucositis.CONCLUSIONOlaparib showed antitumor activity in patients with advanced pancreatic cancer with BRCA1/2 mutations extending findings of recent studies of olaparib in patients with this disease.
AB - PURPOSETargeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with advanced pancreatic cancer with BRCA1/2 mutations treated with olaparib are reported. METHODSEligible patients had advanced pancreatic cancer, measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options available. Genomic testing was performed in Clinical Laboratory Improvement Amendments-certified, College of American Pathologists-accredited site selected laboratories. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease of at least 16 weeks duration (SD16+) according to RECIST v1.1. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of stable disease, and safety.RESULTSThirty patients with BRCA1/2 mutations were enrolled from November 2016 to August 2019. The median number of reported previous therapies was 3 (range, 1-10). Two patients were not evaluable and excluded from efficacy analyses. Two patients with complete response, three with partial response and three with SD16+, were observed for DC and OR rates of 31% (90% CI, 18 to 40; P =.04) and 18% (95% CI, 6 to 37), respectively. The median PFS was 8 (95% CI, 8 to 15) weeks, and the median OS was 38 (95% CI, 21 to 65) weeks. Three patients had at least one drug-related grade 3 adverse event or serious adverse event of anemia, fever, or oral mucositis.CONCLUSIONOlaparib showed antitumor activity in patients with advanced pancreatic cancer with BRCA1/2 mutations extending findings of recent studies of olaparib in patients with this disease.
UR - http://www.scopus.com/inward/record.url?scp=85189498887&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85189498887&partnerID=8YFLogxK
U2 - 10.1200/PO.23.00240
DO - 10.1200/PO.23.00240
M3 - Article
AN - SCOPUS:85189498887
VL - 8
JO - JCO Precision Oncology
JF - JCO Precision Oncology
M1 - e2300240
ER -
